Predictors of Chronic Kidney Disease Among Type 2 Diabetic Patients in Assiut University Hospitals

NCT ID: NCT05847400

Last Updated: 2023-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Globally, the total number of people with diabetes is estimated to increase from 415 million (8.8%) in 2015 to 642 million (10.4%) in 2040, with the largest alterations expected to occur in the urban population of low- to middle-income countries (LMICs)1. Of them, type 2 diabetes mellitus (T2DM) accounts for more than 90% of people with diabetes2,3. By 2040, the difference worldwide is projected to broaden, with 477.9 million affected people living in urban areas and 163.9 million in rural areas1. It has been postulated that the burden of diabetes and its complications in the LMICs may be contributed by the economic development and rapid urbanisation via increased caloric intake and the adoption of a sedentary lifestyle2,4,5. More importantly, the most striking demo graphic change to diabetes prevalence in global terms also seems to be related to the growth of the proportion of the elderly population6. Despite rates of diabetes-related complications such as CVDs decreasing significantly in the past two decades, it has not translated nearly as well as kidney complications7. Approximately 10% of deaths in people with T2DM are attributable to kidney failure8. It is well-established that diabetes-related chronic kidney disease (CKD) is the leading cause of end-stage kidney disease (ESKD) in T2DM patients worldwide9,10.

In our study, we aim to identify and classify patients attending diabetic outpatient clinic with both CKD and

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes With Renal Manifestations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CKD patients with T2DM on regular HD

CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD on regular HD at dialysis unit of Assuit University Hospital

No interventions assigned to this group

CKD patients with T2DM not on regular HD

CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD not on regular HD at dialysis unit of Assuit University Hospital

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients with T2DM aged 18 years or older. For patients whom eGFR values \< or =60 ml/min/1.73m2.

Patient with type 2 DM and ESRD on regular HD with duration less than 1 year

Exclusion Criteria

Having kidney transplantation incomplete data on glycemic control. Patients with type 2 DM and ESRD on regular HD with duration more than 1 year. Pregnant woman. Patients with advanced comorbides(cardiac, hepatic,
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Muhammed Ali Aboalsaud

Aboalsaud

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhammed Al Abualsaud

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Muhammed Al Abualsaud

Role: CONTACT

‪+20 106 923 9438‬

Peter At Munir

Role: CONTACT

01553529181

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Muhammed Al Abualsaud, Master

Role: primary

‪+20 106 923 9438‬

Peter At Munir

Role: backup

01553529181

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ckd in tybe 2 dm

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chronic Kidney Disease in Pregnant Females
NCT06738069 NOT_YET_RECRUITING